🇺🇸 FDA
Pipeline program

XEOMIN 200 V pulveris injekciju šķīduma pagatavošanai, Placebo to NT201, XEOMIN, 200 jednostek, proszek do sporządzania roztworu do wstrzykiwań

M602011072

Phase 3 small_molecule active

Quick answer

XEOMIN 200 V pulveris injekciju šķīduma pagatavošanai, Placebo to NT201, XEOMIN, 200 jednostek, proszek do sporządzania roztworu do wstrzykiwań for Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP) is a Phase 3 program (small_molecule) at Merz Pharmaceuticals GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Merz Pharmaceuticals GmbH
Indication
Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials